Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
could not collect adequate samples
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine if nitrates and IL-8 (which are found in food and throughout the body regulating stomach acidity) play a role in Barrett's Esophagus and/or Esophageal Adenocarcinoma severity and if screening for these biomarkers can help predict patients that are more at risk for developing worsening disease.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1-NSE | Patients found to have grossly normal squamous epithelium during endoscopy | ||
| Group 2-EEG | Patients found to have grossly apparent erosive esophagitis >1cm with Los Angeles Classification A-D | ||
| Group 3-NDBE Short | Patients with non-dysplastic Barrett's Esophagus (NDBE) > 1cm (Short Segment) | ||
| Group 4-NDBE Long | Patients with non-dysplastic Barrett's Esophagus (NDBE) > 1cm (Long Segment) | ||
| Group 5 | Barrett's Esophagus (BE) with high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) | ||
| Group 6-Esophagectomy | Patients undergoing resection of esophageal cancer | ||
| Group -7 Pilot and Feasibility | Patients undergoing EGD with NSE, NDBE, BE-HGD, or EAC for feasibility of analytical techniques |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Nitrate Levels | Nitrate levels in serum, saliva and tissue in patients with normal squamous epithelium, erosive esophagitis, non-dysplastic BE (NDBE), and BE with high-grade dysplasia (HGD) or EAC | Baseline |
| Serum and Tissue Biomarkers | Levels of IL-8 in patients diagnosed BE dysplasia and EAC | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Biomarkers and disease progression | Level of IL-8 in serum and tissue in patients with NDBE that progressed to BE | Baseline |
Not provided
Inclusion Criteria:
- Patients undergoing a clinicallly-indicated Esophagogastroduoedoscopy (EGD).
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult individuals scheduled for clinically indicated EGD procedure. Subjects with normal squamous epithelium, erosive esophagitis, or varying degrees of Barrett's Esophagus may be enrolled.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Cadman Leggett, MD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001471 | Barrett Esophagus |
| C562730 | Adenocarcinoma Of Esophagus |
| ID | Term |
|---|---|
| D011230 | Precancerous Conditions |
| D009369 | Neoplasms |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D004066 |
| Digestive System Diseases |